Who We Are
Investor RelationsNews

Maximized compliance in MLR reviews for a global biotech ​

The Customer

One of the world’s largest global biotech organization serving millions of patients world wide and deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illness


  • Lack of balance between marketers, who are striving to ensure assets (promotional and non-promotional) reach the markets faster, and regulators who are becoming more stringent in protecting patient rights and ensuring HCPs and patients receive complete, accurate and fair-balanced information​

    Explosion in volume of marketing assets to pass through MLR process resulting in increased review time and costs. 50 to 80% preventable errors, resulted in multiple review cycles​

The Solution

We implemented a full-thickness Promotional and Medical Review (PMR) that simplifies and speeds up reviews & approvals of promotional and non-promotional assets, for all 11 brands, across all EU markets.This augments review processes with modern technologies such as RPA, AI/ML, and NLP to improve accuracy, productivity, and efficiency of PMR.It also identifies bottlenecks, uses innovative resource allocation models, adopts efficient SOPs, invests in continuous training, and focuses on continuous improvement for operational efficiencies.


The client is able to mitigate risk of exposure and meet company diligence requirements for all types of content and communication channels.

They can successfully complete co-creation meetings for brands under review, and establish independent review on all products to be future ready and exceed expectations on CSAT survey.

They are able to accept and implement >90% comments by agencies and improve TAT to 1-2 days for >80% of assets.


Review hours effort saved


Reviews completed before due date


Assets approved in first round of review